More Business Briefs
- Business briefs: Medtronic, AMA, Komen, GSK, Lilly, AZN
- Business briefs: Novo Nordisk, Eli Lilly, Merck
- Business briefs: Medscape, Livestrong, ACA, Lilly
- Business briefs: Boehringer Ingelheim, Teva, Medicare
- Business briefs: GSK, DOJ, Sanofi, Flashpoint Medica
GlaxoSmithKline dedicated a new $300,000 production facility at its Nashik site in India to the manufacture of albendazole as part of the World Health Organization's anti-lymphatic filariasis program. The plant will produce 300 million treatments of the drug per year. Lymphatic filariasis, or elephantitis, is a tropical parasitic infection spread by mosquitoes and causing grotesque, painful swelling of the limbs, breasts and genitals. An estimated 120 million people in 83 countries are currently infected.